ATMP Task Force holds workshop in Bergisch-Gladbach
The genetic and cellular engineering experts of the ATMP Task Force met on July for a workshop, which was hosted by BIO Deutschland member Miltenyi Biotec. Also participating was Klaus Cichutek from the Paul-Ehrlich-Institut – Federal Agency for Sera and Vaccines (PEI), who gave an introductory talk on the regulatory challenges facing advanced therapy medicinal products (ATMPs). The experts then discussed the current challenges and obstacles along the value chain. They agreed that a gene or cell therapy poses a major challenge, and that the current framework conditions are not always suitable for such ATMPs. The task force also identified potential improvements for research and development in this field, and now seek to verify these. It plans to continue the very constructive exchange with the PEI.